Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02654587 · ClinicalTrials.gov registry record · Phase 3
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
A Phase 3 study, sponsored by OSE Immunotherapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 219
- Enrollment target
NCT02654587 is a Phase 3 study that was terminated before completion, run by OSE Immunotherapeutics. The registered enrollment target is 219 participants.
The verdict
NCT02654587, a Phase 3 study, was terminated before completion, sponsored by OSE Immunotherapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 219 participants
- Enrollment target
Study Summary
The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC who progressed after sequential or concurrent chemotherapy and immune checkpoint inhibitor given in first or second-line treatment. The main questions were to compare the survival, the tolerance to treatment and the quality of life of patients between the two arms of treatment (OSE2101 versus standard chemotherapy)
Interventions
- DRUG Docetaxel
- DRUG Pemetrexed
- BIOLOGICAL OSE2101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2016-02-12 |
| Est. Completion | 2021-01-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02654587
The ClinicalTrials.gov registry entry for NCT02654587 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OSE Immunotherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT02654587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02654587 about?
NCT02654587 is a clinical study titled "OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure". The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC who progressed after sequential or concurrent chemotherapy and immune ...
What is the current status of trial NCT02654587?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 219 participants. The study started on 2016-02-12. Estimated completion is 2021-01-15.
What interventions are being tested in trial NCT02654587?
The interventions under investigation include: Docetaxel (DRUG), Pemetrexed (DRUG), OSE2101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02654587?
This trial is sponsored by OSE Immunotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.